Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

"This may inform prescribing of glucose-lowering medications among patients with T2D and active COPD," making SGLT2 and GLP-1 drugs preferable over DPP-4 inhibitors for these patients, the group ...

There are certain risk factors for COPD, including obesity and having type 2 diabetes. A new study has found that people who have type 2 diabetes who are treated with GLP-1 and SGLT-2 medications ...

The most essential step in any treatment plan for COPD is to stop smoking. Quitting smoking isn’t easy, but nicotine replacement products and medications might help. Other treatment options ...

and behaviors of COPD patients self-reporting good adherence with those of patients reporting suboptimal adherence to their medications. Design: Cross-sectional self-administered questionnaire.

By Dr. Priyom Bose, Ph.D. Certain glucose-lowering drugs were linked to fewer moderate or severe COPD exacerbations in adults with type 2 diabetes Study: Glucose-Lowering Medications and Risk of ...